tiprankstipranks
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
Holding RARE?
Track your performance easily

Ultragenyx Pharmaceutical (RARE) Ownership - Who Owns Ultragenyx Pharmaceutical?

755 Followers

Ultragenyx Pharmaceutical (RARE) Ownership Overview

3.98%29.88%36.83%14.53%14.79%
36.83% Other Institutional Investors
14.53% ETFs
14.79% Public Companies and Individual Investors
The ownership structure of Ultragenyx Pharmaceutical (RARE) stock is a mix of institutional, retail, and individual investors. Approximately 81.23% of the company’s stock is owned by Institutional Investors, 3.98% is owned by Insiders, and 14.79% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Oct 11, 2024
xxxxxxxxxxxxx
$393853
Sep 05, 2024
Emil Kakkis
President & Ceo,director
xxxxxxxxxxxxx
$1117000
Aug 07, 2024
Emil Kakkis
President & Ceo,director
xxxxxxxxxxxxx
$1003400
Jul 03, 2024
xxxxxxxxxxxxx
$23932

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
8,074,082Institution8.74%361,315,170
7,366,916Institution7.98%329,669,491
5,118,255Institution5.54%229,041,911
2,788,582Insider3.02%124,789,045
2,249,682Institution2.44%100,673,270
2,190,840Institution2.37%98,040,090
2,082,400Institution2.26%93,187,400
1,787,637Institution1.94%79,996,756
1,466,547Institution1.59%65,627,978
1,462,138Institution1.58%65,430,676

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
7,366,916Institution7.98%329,669,491
2,190,840Institution2.37%98,040,090
2,082,400Institution2.26%93,187,400
1,787,637Institution1.94%79,996,756
1,462,138Institution1.58%65,430,676
1,082,366Institution1.17%48,435,879
974,312Institution1.06%43,600,462
949,273Institution1.03%42,479,967
942,508Institution1.02%42,177,233
900,881Institution0.98%40,314,425

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
2,809,832Institution3.04%156,086,168
2,191,348Institution2.37%121,729,381
1,379,587Institution1.49%76,636,058
1,208,644Institution1.31%67,140,174
1,131,762Institution1.23%53,917,142
593,788Institution0.64%26,572,013
498,246Institution0.54%22,296,509
481,209Institution0.52%21,534,103
446,328Institution0.48%21,263,066
270,591Institution0.29%15,031,330

FAQ

Who Owns Ultragenyx Pharmaceutical (RARE)?
According to the latest TipRanks data, approximately 36.83% of the company's stock is held by institutional investors, 3.98% is held by insiders, and 14.79% is held by retail investors.
    What percentage of Ultragenyx Pharmaceutical (RARE) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 36.83% of Ultragenyx Pharmaceutical (RARE) stock is held by institutional investors.
      What percentage of Ultragenyx Pharmaceutical (RARE) stock is held by retail investors?
      According to the latest TipRanks data, approximately 14.79% of Ultragenyx Pharmaceutical (RARE) stock is held by retail investors.
        Who owns the most shares of Ultragenyx Pharmaceutical (RARE)?
        Vanguard owns the most shares of Ultragenyx Pharmaceutical (RARE).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis